日本首先批准以母乳为基础的人体营养强化剂为早产婴儿处方药。 Japan approves first human milk-based fortifiers as prescription drugs for premature infants.

日本已成为第一个批准Prolacta生物科学公司百分之百以母乳为基础的人体营养强化剂 -- -- Premiefort 6、8和第三种配方 -- -- 作为脆弱婴儿(包括出生体重极低的婴儿和有严重医疗条件的婴儿)处方药物的国家。 Japan has become the first country to approve Prolacta Bioscience’s 100% human milk-based fortifiers—PreemieFort 6, 8, and a third formulation—as prescription drugs for fragile infants, including very low birth weight babies and those with serious medical conditions. 日本卫生、劳动和福利部在PPDA的支持下,在第三阶段临床试验显示增长改善而没有增加风险后,批准了这项试验。 The approval by Japan’s Ministry of Health, Labour and Welfare, backed by the PMDA, follows a phase III clinical trial showing improved growth without increased risk. 这些产品按药级标准制成,每批配有葡萄消毒和20多次安全测试,保存免疫增强成分。 The products, made under pharmaceutical-grade standards with vat pasteurization and over 20 safety tests per batch, preserve immune-boosting components. 这一举动标志着全球首创行动,承认以母乳为基础的人类营养是基本医疗疗法。 The move marks a global first, recognizing human milk-based nutrition as essential medical therapy.